Idorsia lays off up to 300 people, plans for pipeline prioritization in effort to extend cash runway
Idorsia revealed a major cost reduction initiative on Tuesday, laying off up to 300 people and reviewing its pipeline for programs to cut or out-license. The restructuring follows a warning in July, when the company said it was looking to reduce its cash burn by half as it works to build its insomnia drug sales.
The company said 475 jobs at its headquarters in Switzerland had been “made redundant” by canceling open jobs, not replacing people who left and laying off up to 300 people mostly in R&D. Idorsia said it plans to finish the cost-cutting initiative before the end of the year, with it becoming “fully effective” at the beginning of 2024. Cutting jobs cost the company CHF 11 million ($12.3 million).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.